Skip to main content
Premium Trial:

Request an Annual Quote

Epidauros Licenses Drug Metabolism Biomarker to Osmetech to Push Into PGx

NEW YORK (GenomeWeb News) — Osmetech will use Epidauros Biotechnologies’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing, the companies said today.
 
The diagnostic healthcare company has signed a non-exclusive licensing agreement to use the IP to the genetic variant 2988G>A, which it will use in combination with other variants as predictive markers in its molecular and critical care diagnostic ventures.
 
Financial details were not disclosed.
 
Epidauros, a German pharmacogenomics services company, entered into a similar licensing agreement with the same biomarker with Bioscience Corp this spring for services concerning. That deal included an up-front signing fee and royalties.  
 
Osmetech, based in Pasadena, Calif., currently has a cystic fibrosis product on the market and plans to make its e-Sensor platform its first entry into pharmacogenomics.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.